HK1078896A1 - Method for manufacturing recombinant polyclonal proteins - Google Patents
Method for manufacturing recombinant polyclonal proteinsInfo
- Publication number
- HK1078896A1 HK1078896A1 HK05110692A HK05110692A HK1078896A1 HK 1078896 A1 HK1078896 A1 HK 1078896A1 HK 05110692 A HK05110692 A HK 05110692A HK 05110692 A HK05110692 A HK 05110692A HK 1078896 A1 HK1078896 A1 HK 1078896A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cells
- collection
- library
- nucleic acid
- recombinant polyclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43840303P | 2003-01-07 | 2003-01-07 | |
DKPA200300008 | 2003-01-07 | ||
US47601803P | 2003-06-05 | 2003-06-05 | |
PCT/DK2004/000001 WO2004061104A2 (en) | 2003-01-07 | 2004-01-07 | Method for manufacturing recombinant polyclonal proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1078896A1 true HK1078896A1 (en) | 2006-03-24 |
Family
ID=32718469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05110692A HK1078896A1 (en) | 2003-01-07 | 2005-11-25 | Method for manufacturing recombinant polyclonal proteins |
Country Status (19)
Country | Link |
---|---|
US (1) | US9163232B2 (de) |
EP (2) | EP1583830B1 (de) |
JP (2) | JP4589914B2 (de) |
KR (1) | KR101024443B1 (de) |
AT (1) | ATE338816T1 (de) |
AU (1) | AU2004203727C1 (de) |
BR (1) | BRPI0406678A (de) |
CA (1) | CA2512647C (de) |
DE (1) | DE602004002275T2 (de) |
DK (1) | DK1583830T3 (de) |
EA (1) | EA013225B1 (de) |
ES (1) | ES2273202T3 (de) |
HK (1) | HK1078896A1 (de) |
IL (1) | IL169101A (de) |
MX (1) | MXPA05006724A (de) |
NZ (1) | NZ541458A (de) |
PT (1) | PT1583830E (de) |
SI (1) | SI1583830T1 (de) |
WO (1) | WO2004061104A2 (de) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
EP2314629B2 (de) | 2002-07-18 | 2022-11-16 | Merus N.V. | Rekombinante Herstellung von Mischungen aus Aantikörpern |
SI1583830T1 (sl) | 2003-01-07 | 2006-12-31 | Symphogen As | Postopek za pripravo rekombinantnih poliklonskih proteinov |
TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
EP1967529A1 (de) * | 2004-07-20 | 2008-09-10 | Symphogen A/S | Rekombinanter polyklonaler Anti-Rhesus-D-Antikörper und Herstellungsverfahren |
DK1787126T3 (da) * | 2004-07-20 | 2009-12-21 | Symphogen As | Fremgangsmåde til karakterisering af en polyklonal cellelinie |
EP1907561B1 (de) * | 2005-06-24 | 2013-08-28 | Unigene Laboratories, Inc. | Zellinien zur expression eines bei der herstellung amidierter produkte geeigneten enzyms |
US7850965B2 (en) | 2005-12-05 | 2010-12-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
MX2008011280A (es) * | 2006-03-06 | 2008-09-12 | Symphogen As | Anticuerpor policlonal recombinante para el tratamiento de infecciones por el virus sincitial respiratorio. |
US7504106B2 (en) | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
FR2910490B1 (fr) * | 2006-12-20 | 2012-10-26 | Lab Francais Du Fractionnement | Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques |
US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
WO2008097926A2 (en) * | 2007-02-02 | 2008-08-14 | Yale University | Transient transfection with rna |
US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
TW200846362A (en) * | 2007-02-09 | 2008-12-01 | Symphogen As | A polyclonal antibody product |
JP5669397B2 (ja) | 2007-03-01 | 2015-02-12 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 同族抗体をクローニングするための方法 |
NZ597466A (en) | 2007-03-01 | 2013-08-30 | Symphogen As | Recombinant anti-epidermal growth factor receptor antibody compositions |
CN101679513A (zh) * | 2007-03-06 | 2010-03-24 | 西福根有限公司 | 用于治疗呼吸道合胞病毒感染的重组抗体 |
AU2008255383B2 (en) * | 2007-05-25 | 2012-11-01 | Symphogen A/S | Method for manufacturing a recombinant polyclonal protein |
PT2199390T (pt) | 2007-08-30 | 2017-03-15 | Daiichi Sankyo Co Ltd | Anticorpo anti-epha2 |
EP2725035A1 (de) | 2007-10-02 | 2014-04-30 | Avaxia Biologics, Inc. | Antikörpertherapie zur Verwendung im Verdauungstrakt |
KR101534884B1 (ko) | 2007-10-11 | 2015-07-08 | 다이이찌 산쿄 가부시키가이샤 | 파골 세포 관련 단백질 Siglec-15 를 표적으로 한 항체 |
CA2722348A1 (en) * | 2008-04-23 | 2009-10-29 | Symphogen A/S | Methods for manufacturing a polyclonal protein |
EP2331577B1 (de) | 2008-08-29 | 2017-06-07 | Symphogen A/S | Zusammensetzungen rekombinanter antikörper gegen den rezeptor des epidermalen wachstumsfaktors |
EP2331689A4 (de) * | 2008-08-29 | 2012-10-31 | Symphogen As | Verfahren zum klonen von antikörpern aus vögeln |
KR101690340B1 (ko) | 2009-04-09 | 2016-12-27 | 다이이찌 산쿄 가부시키가이샤 | 항 Siglec-15 항체 |
HUE027077T2 (en) | 2009-10-15 | 2016-08-29 | Avaxia Biologics Inc | Antibody therapy with local activity in the digestive system |
DK2636736T3 (en) | 2010-10-29 | 2016-07-04 | Daiichi Sankyo Co Ltd | Novel anti-dr5 antibody |
DK2635604T3 (en) | 2010-11-01 | 2017-02-27 | Symphogen As | PAN-HER-ANTIBODY COMPOSITION |
WO2012068317A2 (en) | 2010-11-16 | 2012-05-24 | Excelimmune, Inc. | Methods for producing recombinant proteins |
KR102030987B1 (ko) | 2011-04-25 | 2019-11-11 | 다이이찌 산쿄 가부시키가이샤 | 항 b7-h3항체 |
US9963511B2 (en) | 2011-12-22 | 2018-05-08 | Hoffmann-La Roche Inc. | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
CA2868965A1 (en) | 2012-03-30 | 2013-10-03 | Daiichi Sankyo Company, Limited | Anti-siglec-15 antibody |
KR20150003170A (ko) | 2012-03-30 | 2015-01-08 | 다이이찌 산쿄 가부시키가이샤 | CDR 개변 항 Siglec-15 항체 |
NZ631445A (en) | 2012-04-09 | 2017-02-24 | Daiichi Sankyo Co Ltd | Anti-fgfr2 antibody |
JP6393255B2 (ja) | 2012-04-20 | 2018-09-19 | メルス ナムローゼ フェンノートシャップ | ヘテロ二量体のIgG様分子を生産する方法、ヘテロ二量体のIgG様分子、ヘテロ二量体の抗体、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法、および培養物 |
MY166821A (en) | 2012-04-27 | 2018-07-23 | Daiichi Sankyo Co Ltd | Anti-robo4-antibody |
EP2844675B1 (de) | 2012-05-02 | 2019-01-02 | Symphogen A/S | Humanisierte pan-her-antikörperzusammensetzungen |
JP2015163047A (ja) * | 2012-06-20 | 2015-09-10 | 国立大学法人 東京大学 | タンパク質の迅速改良法 |
AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
EA201590640A1 (ru) | 2012-09-27 | 2015-11-30 | Мерюс Б.В. | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА КЛАССА IgG В КАЧЕСТВЕ РЕКРУТЕРОВ Т-КЛЕТОК |
JP2016514091A (ja) | 2013-02-08 | 2016-05-19 | ミスフォールディング ダイアグノスティクス, インコーポレイテッド | トランスサイレチン抗体およびその使用 |
BR112016006428A2 (pt) | 2013-09-30 | 2017-09-26 | Daiichi Sankyo Co Ltd | anticorpo, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, métodos para tratamento e/ou profilaxia de infecção por pseudomona e para produzir um anticorpo, agente de diagnóstico para infecção por pseudomona, kit de detecção para pseudomonas aeruginosa, polinucleotídeo, vetor, e, célula hospedeira transformada |
JP6509735B2 (ja) | 2013-10-08 | 2019-05-08 | 第一三共株式会社 | 抗fgfr2抗体と他剤の組合せ |
WO2015093925A1 (es) * | 2013-12-19 | 2015-06-25 | CASTRO ALDRETE, Jorge Isaac | Método de producción de anticuerpos específicos |
AU2015223566B2 (en) | 2014-02-28 | 2020-10-08 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
AU2015223567B2 (en) | 2014-02-28 | 2020-09-10 | Merus N.V. | Antibody that binds ErbB-2 and ErbB-3 |
CN107001471B (zh) | 2014-09-16 | 2022-01-18 | 西福根有限公司 | 抗met抗体和组合物 |
ES2904573T3 (es) | 2015-03-27 | 2022-04-05 | Univ Southern California | Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos |
WO2016197064A1 (en) | 2015-06-04 | 2016-12-08 | Epstein Alan L | Lym-1 and lym-2 targeted car cell immunotherapy |
ES2693596T3 (es) | 2015-07-10 | 2018-12-12 | Merus N.V. | Anticuerpo que se une a CD3 humano |
KR20180053744A (ko) | 2015-09-23 | 2018-05-23 | 사이토이뮨 테라퓨틱스 엘엘씨 | 면역 요법을 위한 flt3 유도된 car 세포 |
CA2999819A1 (en) | 2015-09-24 | 2017-03-30 | Daiichi Sankyo Company, Limited | Anti-garp antibody |
PL3365373T3 (pl) | 2015-10-23 | 2021-08-23 | Merus N.V. | Molekuły wiążące, które hamują wzrost nowotworu |
EP3463451A1 (de) | 2016-05-26 | 2019-04-10 | Qilu Puget Sound Biotherapeutics Corporation | Mischungen aus antikörpern |
KR20190121294A (ko) | 2016-12-22 | 2019-10-25 | 다이이찌 산쿄 가부시키가이샤 | 항-cd3 항체, 및 항-cd3 항체를 포함하는 분자 |
CA3052938A1 (en) | 2017-02-07 | 2018-08-16 | Daiichi Sankyo Company, Limited | Anti-gprc5d antibody and molecule comprising the antibody |
TWI782000B (zh) | 2017-03-30 | 2022-11-01 | 日商第一三共股份有限公司 | 抗gpr20抗體、其製造方法及其應用 |
IL269656B1 (en) | 2017-03-31 | 2024-02-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
US11939380B2 (en) | 2017-04-05 | 2024-03-26 | Les Laboratoires Servier | Combination therapies targeting PD-1, TIM-3, and LAG-3 |
CN110913905A (zh) | 2017-06-30 | 2020-03-24 | 国立大学法人北海道大学 | 不产生生长障碍的小儿骨质疏松症治疗药 |
US11661451B2 (en) | 2017-07-27 | 2023-05-30 | Daiichi Sankyo Company, Limited | Anti-CD147 antibody |
CN111094351A (zh) | 2017-08-09 | 2020-05-01 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
BR112020006860A2 (pt) | 2017-10-05 | 2020-10-20 | Daiichi Sankyo Company, Limited | composição para depleção de células t citotóxicas |
JP7419248B2 (ja) | 2017-12-11 | 2024-01-22 | アバローニー バイオ,インコーポレーテッド | ペリプラズム空間中におけるタンパク質の酵母ディスプレイ |
AU2019231380A1 (en) | 2018-03-05 | 2020-09-24 | Daiichi Sankyo Company, Limited | Pharmaceutical composition for treating or preventing heterotopic ossification |
BR112020021266A2 (pt) | 2018-05-31 | 2021-01-26 | Daiichi Sankyo Company, Limited | anticorpo anti-tlr7 humano |
US20210269509A1 (en) | 2018-06-22 | 2021-09-02 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
TW202035449A (zh) | 2018-07-10 | 2020-10-01 | 國立大學法人神戶大學 | 抗SIRPα抗體 |
US20210169852A1 (en) | 2018-07-27 | 2021-06-10 | Daiichi Sankyo Company, Limited | Protein recognizing drug moiety of antibody-drug conjugate |
EP4008350A4 (de) | 2019-07-26 | 2023-06-14 | Saitama Medical University | Antikörper, der die extrazelluläre region von alk2/acvr1 erkennt |
WO2021079958A1 (ja) | 2019-10-25 | 2021-04-29 | 第一三共株式会社 | 抗garp抗体と免疫調節剤の組み合わせ |
CA3166364A1 (en) | 2019-12-31 | 2021-07-08 | Antagonis | Compositions and methods for the prevention of s. aureus infection |
CA3177152A1 (en) | 2020-06-12 | 2021-12-16 | David Scott Johnson | Recombinant polyclonal proteins targeting covid-19 and methods of use thereof |
WO2022031834A1 (en) | 2020-08-05 | 2022-02-10 | Gigagen, Inc. | Recombinant polyclonal proteins targeting zika and methods of use thereof |
EP4204005A1 (de) | 2020-08-31 | 2023-07-05 | Sab, Llc | Von ungulat abgeleitetes polyklonales immunglobulin, das spezifisch für coronavirusprotein ist, und verwendungen davon |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US155114A (en) * | 1874-09-15 | Improvement in methods of laying and forming cast-iron pipes | ||
CA1293460C (en) * | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
WO1991016074A1 (en) | 1990-04-19 | 1991-10-31 | Medimmune, Inc. | Administration of monoclonal antibodies against respiratory viruses |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
WO1992015694A1 (en) | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
DK1231268T3 (da) * | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
US6111166A (en) | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
ES2242997T3 (es) * | 1997-03-14 | 2005-11-16 | Biogen Idec Inc. | Metodo para integrar genes en sitios especificos en celulas de mamifero por medio de recombinacion homologa y vectores para realizar el mismo. |
US6368821B1 (en) | 1997-04-14 | 2002-04-09 | Stratagene | Process for infecting eukaryotic cells with a bacterial virus |
AU5898599A (en) * | 1998-08-19 | 2000-03-14 | Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for genomic modification |
US20020155114A1 (en) | 1998-08-31 | 2002-10-24 | James D. Marks | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
CA2373690A1 (en) | 1999-07-14 | 2001-01-25 | Clontech Laboratories, Inc. | Recombinase-based methods for producing expression vectors and compositions for use in practicing the same |
JP4808880B2 (ja) | 1999-07-23 | 2011-11-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | バクテリオファージphic31組み換え系による真核細胞におけるdna組み換え |
DK1283720T3 (da) * | 2000-05-26 | 2007-08-13 | Symphogen As | Rekombinante eller rensede polyklonale antistoffer til behandling af allergi |
WO2001094571A1 (fr) | 2000-06-08 | 2001-12-13 | Mitsubishi Pharma Corporation | Vecteur d'expression permettant le criblage de cellules a haute expression de proteine de recombinaison, transformant a haute expression de proteine de recombinaison, et leur utilisation |
US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
US6610472B1 (en) * | 2000-10-31 | 2003-08-26 | Genetastix Corporation | Assembly and screening of highly complex and fully human antibody repertoire in yeast |
CA2430080A1 (en) * | 2000-11-28 | 2002-06-06 | Applied Molecular Evolution, Inc. | Eukaryotic expression libraries based on double lox recombination and methods of use |
US20030044398A1 (en) | 2001-03-20 | 2003-03-06 | Robl James M. | Methods for producing antibodies in mammals |
EP2314629B2 (de) | 2002-07-18 | 2022-11-16 | Merus N.V. | Rekombinante Herstellung von Mischungen aus Aantikörpern |
AU2003283995A1 (en) | 2002-09-30 | 2004-04-19 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
SI1583830T1 (sl) | 2003-01-07 | 2006-12-31 | Symphogen As | Postopek za pripravo rekombinantnih poliklonskih proteinov |
US20060275766A1 (en) | 2003-01-07 | 2006-12-07 | Haurum John S | Method for manufacturing recombinant polyclonal proteins |
TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
AU2005206251A1 (en) | 2004-01-21 | 2005-08-04 | Novozymes A/S | Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell |
EP1967529A1 (de) | 2004-07-20 | 2008-09-10 | Symphogen A/S | Rekombinanter polyklonaler Anti-Rhesus-D-Antikörper und Herstellungsverfahren |
DK1787126T3 (da) | 2004-07-20 | 2009-12-21 | Symphogen As | Fremgangsmåde til karakterisering af en polyklonal cellelinie |
US7850965B2 (en) | 2005-12-05 | 2010-12-14 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
MX2008011280A (es) | 2006-03-06 | 2008-09-12 | Symphogen As | Anticuerpor policlonal recombinante para el tratamiento de infecciones por el virus sincitial respiratorio. |
TW200846362A (en) | 2007-02-09 | 2008-12-01 | Symphogen As | A polyclonal antibody product |
AU2008255383B2 (en) | 2007-05-25 | 2012-11-01 | Symphogen A/S | Method for manufacturing a recombinant polyclonal protein |
-
2004
- 2004-01-07 SI SI200430074T patent/SI1583830T1/sl unknown
- 2004-01-07 DE DE602004002275T patent/DE602004002275T2/de not_active Expired - Lifetime
- 2004-01-07 CA CA2512647A patent/CA2512647C/en not_active Expired - Fee Related
- 2004-01-07 WO PCT/DK2004/000001 patent/WO2004061104A2/en active IP Right Grant
- 2004-01-07 ES ES04700438T patent/ES2273202T3/es not_active Expired - Lifetime
- 2004-01-07 EP EP04700438A patent/EP1583830B1/de not_active Expired - Lifetime
- 2004-01-07 DK DK04700438T patent/DK1583830T3/da active
- 2004-01-07 MX MXPA05006724A patent/MXPA05006724A/es active IP Right Grant
- 2004-01-07 AT AT04700438T patent/ATE338816T1/de active
- 2004-01-07 BR BR0406678-2A patent/BRPI0406678A/pt not_active Application Discontinuation
- 2004-01-07 AU AU2004203727A patent/AU2004203727C1/en not_active Ceased
- 2004-01-07 EP EP06018504A patent/EP1762617A1/de not_active Withdrawn
- 2004-01-07 PT PT04700438T patent/PT1583830E/pt unknown
- 2004-01-07 EA EA200501101A patent/EA013225B1/ru not_active IP Right Cessation
- 2004-01-07 NZ NZ541458A patent/NZ541458A/en not_active IP Right Cessation
- 2004-01-07 JP JP2006500508A patent/JP4589914B2/ja not_active Expired - Fee Related
- 2004-01-07 KR KR1020057012745A patent/KR101024443B1/ko not_active IP Right Cessation
-
2005
- 2005-06-09 IL IL169101A patent/IL169101A/en not_active IP Right Cessation
- 2005-11-25 HK HK05110692A patent/HK1078896A1/xx not_active IP Right Cessation
-
2008
- 2008-12-19 US US12/339,490 patent/US9163232B2/en not_active Expired - Fee Related
-
2010
- 2010-07-08 JP JP2010155716A patent/JP2010268806A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BRPI0406678A (pt) | 2005-12-20 |
JP2010268806A (ja) | 2010-12-02 |
WO2004061104A2 (en) | 2004-07-22 |
DE602004002275T2 (de) | 2007-09-06 |
SI1583830T1 (sl) | 2006-12-31 |
DE602004002275D1 (de) | 2006-10-19 |
WO2004061104A3 (en) | 2004-11-04 |
EP1583830A2 (de) | 2005-10-12 |
KR20050101538A (ko) | 2005-10-24 |
EP1762617A1 (de) | 2007-03-14 |
US20090136498A1 (en) | 2009-05-28 |
JP4589914B2 (ja) | 2010-12-01 |
AU2004203727C1 (en) | 2008-08-21 |
PT1583830E (pt) | 2006-11-30 |
AU2004203727B2 (en) | 2008-01-31 |
EP1583830B1 (de) | 2006-09-06 |
CA2512647A1 (en) | 2004-07-22 |
CA2512647C (en) | 2013-10-08 |
ATE338816T1 (de) | 2006-09-15 |
US9163232B2 (en) | 2015-10-20 |
EA013225B1 (ru) | 2010-04-30 |
DK1583830T3 (da) | 2007-01-15 |
KR101024443B1 (ko) | 2011-03-23 |
NZ541458A (en) | 2006-04-28 |
EA200501101A1 (ru) | 2006-02-24 |
IL169101A (en) | 2009-02-11 |
AU2004203727A1 (en) | 2004-07-22 |
ES2273202T3 (es) | 2007-05-01 |
MXPA05006724A (es) | 2005-09-08 |
JP2006515520A (ja) | 2006-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1078896A1 (en) | Method for manufacturing recombinant polyclonal proteins | |
CN104854133B (zh) | 用于制备重组抗体治疗剂的最佳重链和轻链信号肽 | |
JP6573331B2 (ja) | 同起源の抗体可変領域遺伝子セグメントをクローニングおよび発現させるための迅速な方法 | |
HK1134519A1 (en) | Method for manufacturing a recombinant polyclonal protein | |
CN104011080B (zh) | 用于真核细胞的全长抗体展示系统及其用途 | |
NO20020861D0 (no) | PD-1, en reseptor for B7-4, og anvendelser derav | |
Kurosawa et al. | Rapid production of antigen-specific monoclonal antibodies from a variety of animals | |
CN105602960A (zh) | 抗体的快速人源化 | |
DE60039596D1 (de) | Verfahren zur herstellung von monoklonalen antikörpern | |
JPH0335800A (ja) | ヘテロ二重特異性モノクローナル抗体の製造法 | |
ATE366814T1 (de) | Gl50 moleküle, sowie verwendungen derselben | |
ATE498013T1 (de) | Für zellzyklusproteine kodierende nukleinsäure und deren verwendung | |
Price et al. | Engineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomas | |
US8663980B2 (en) | Vectors, host cells, and methods of production and uses | |
CN106478773A (zh) | 一种人工合成的新型信号肽 | |
ES2700442T3 (es) | Método para producir anticuerpos | |
CN106478774A (zh) | 一种用于蛋白质表达的信号肽 | |
CN104558180B (zh) | 靶向t淋巴细胞的人源单链抗体 | |
CN102731656A (zh) | 一种重组抗opn单克隆抗体及其制备方法和用途 | |
WO2001064894A3 (en) | Human phospholipid scramblase-like molecules and uses thereof | |
CN110483641A (zh) | 干扰素诱导型gtp酶的单克隆抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20140107 |